Semaglutide in Australia 2026: Ozempic vs Wegovy — What Is the Difference?

Semaglutide is now one of the most prescribed — and most searched-for — medications in Australia. But there is widespread confusion about the difference between Ozempic and Wegovy, both of which contain semaglutide as their active ingredient. This guide explains everything clearly.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a synthetic medication that mimics glucagon-like peptide-1 (GLP-1), a gut hormone released naturally after eating. Developed by Novo Nordisk, semaglutide activates GLP-1 receptors in the brain, gut, and pancreas to produce several simultaneous effects:

• Significantly reduced appetite and food cravings
• Slower gastric emptying (you feel full faster and stay full longer)
• Improved insulin secretion and blood glucose regulation
• Reduced caloric intake without requiring deliberate dietary restriction

For a detailed clinical overview, the RACGP's obesity management guidelines summarise GLP-1 pharmacology and its applications in Australian primary care.

Ozempic vs Wegovy: Same Molecule, Different Products

In Australia, semaglutide is available under two brand names with important differences:

Ozempic (semaglutide 0.25mg–2mg)

• TGA-approved for type 2 diabetes management
• Available in 0.25mg, 0.5mg, 1mg, and 2mg weekly doses
• PBS-subsidised for type 2 diabetes in eligible patients (~$31 per script for general patients)
• Widely prescribed off-label for weight management — legal and common clinical practice in Australia
• Private prescription cost for weight loss: $120–$220 per month

Wegovy (semaglutide 2.4mg)

• TGA-approved specifically for chronic weight management in adults
• Single target dose of 2.4mg/week, reached via a 5-month titration schedule
• Not currently PBS-listed for weight management — private prescription only
• Higher maximum dose produces greater weight loss than Ozempic's 2mg ceiling
• Cost: $200–$280 per month at maintenance dose

Clinical Trial Evidence for Semaglutide

Semaglutide has one of the strongest evidence bases in weight management history.

STEP-1 Trial — Weight Loss Efficacy

Published in the New England Journal of Medicine (2021), the STEP-1 trial enrolled 1,961 adults with obesity but without type 2 diabetes. Those receiving semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. 86% of participants achieved at least 5% weight loss; 69% achieved at least 10%.

SELECT Trial — Cardiovascular Outcomes

Published in the New England Journal of Medicine (2023), the SELECT trial enrolled 17,604 adults with pre-existing cardiovascular disease and obesity but without diabetes. Semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% compared to placebo. This landmark trial established semaglutide as a cardiovascular risk reduction treatment, not merely a weight loss drug.

Is Semaglutide Available in Australia?

Yes. Both Ozempic and Wegovy are available in Australia with a valid prescription from a GP. Availability at individual pharmacies varies by dose — calling ahead to confirm stock is advisable. Global supply constraints that affected availability in 2023–2024 have largely resolved, and both products are generally accessible through major pharmacy chains.

The TGA maintains current approved product information for both Ozempic and Wegovy on its website.

Semaglutide vs Tirzepatide (Mounjaro): Which Is Better?

Since Mounjaro became available in Australia, many patients ask how semaglutide compares to tirzepatide. Key differences:

• Mechanism: Semaglutide activates GLP-1 receptors only. Tirzepatide (Mounjaro) activates both GLP-1 and GIP receptors — a dual mechanism that amplifies weight loss further
• Average weight loss: ~15% for semaglutide 2.4mg vs ~21% for tirzepatide 15mg
• Side effects: Broadly similar — primarily gastrointestinal (nausea, vomiting, constipation during titration)
• Cost: Semaglutide is generally cheaper ($200–$280/month for Wegovy vs $310–$350 for Mounjaro at highest doses)

Not all patients need the maximum weight loss — many achieve their goals on semaglutide and never need to escalate. For patients who plateau or who have type 2 diabetes alongside obesity, tirzepatide may offer additional benefit. Your GP will help you make this decision based on your individual health profile and goals.

How to Get a Semaglutide Prescription in Australia

1. Book a GP telehealth consultation — no specialist or in-person visit required
2. Complete a clinical assessment covering BMI, medical history, current medications, and contraindications
3. Receive a prescription for Ozempic or Wegovy based on your clinical needs and discussion with your GP
4. Fill the prescription at a pharmacy — both are stocked at most major Australian pharmacy chains

At Weight Loss GP Australia, consultations are bulk billed for eligible patients under Medicare telehealth item numbers — meaning the GP appointment costs $0 out-of-pocket. The medication itself is a private prescription.

Frequently Asked Questions — Semaglutide in Australia

What is the difference between semaglutide and GLP-1?

GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone. Semaglutide is a synthetic GLP-1 receptor agonist — engineered to mimic GLP-1's effects at a sustained, controlled level far exceeding natural secretion. It binds the same receptors with much greater potency and duration (weekly dosing vs the seconds-long action of natural GLP-1).

Is semaglutide PBS-listed in Australia?

Ozempic (semaglutide) is PBS-listed for type 2 diabetes in patients meeting specific criteria. Wegovy (semaglutide 2.4mg for weight management) is not currently PBS-listed for that indication. Check the PBS website for current listing information.

How long does semaglutide take to work for weight loss?

Most patients notice reduced appetite within the first 1–2 weeks. Meaningful weight reduction (≥5%) typically occurs within the first 8–12 weeks at maintenance dose. Maximum weight loss is generally seen at 12–18 months of continuous treatment.

What happens if I stop taking semaglutide?

Clinical data from the STEP-4 extension trial shows that patients who stopped semaglutide after achieving weight loss regained approximately 7% of body weight within 12 months — and most of the lost weight within two years. The RACGP and international obesity medicine bodies treat obesity as a chronic condition requiring ongoing management, similar to hypertension or dyslipidaemia.

Is semaglutide safe for long-term use?

Semaglutide has been in clinical use since Ozempic's first approval in 2017, and the global safety dataset now encompasses millions of patients over multiple years. The most common side effects are gastrointestinal (nausea, vomiting, constipation) and are most pronounced during dose titration. The TGA and regulatory agencies globally continue to monitor post-marketing safety data. Your GP will review your individual health profile and any risk factors before and during treatment.